Trial Profile
A Phase I/II Study of Eltrombopag in Elderly Patients With AML
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 31 Mar 2023
Price :
$35
*
At a glance
- Drugs Eltrombopag (Primary)
- Indications Acute myeloid leukaemia
- Focus Adverse reactions; Pharmacodynamics
- 06 Apr 2020 Status changed from completed to discontinued.
- 20 Sep 2018 Status changed from active, no longer recruiting to completed.
- 18 Jul 2016 Status changed from completed to active, no longer recruiting.